Sarepta stock spikes as golodirsen study suggests inroads on exon 53

Chatter about a potential NDA filing for golodirsen started as soon as Sarepta Therapeutics Inc. reported that the phase I/II study (4053-101) of the exon 53 skipping candidate achieved statistical significance on its primary and secondary biological endpoints.